Actavis seeks approval for generic Qsymia for treatment of Obesity- Vivus Inc.
Vivus Inc has announced that Actavis Plc plans to market a generic version of Qsymia (phentermine plus topiramate).Actavis has already filed a U.S. marketing application for the generic version of the drug, according to a notice sent by Actavis on 7 May 2014. Qsymia was one of the first obesity drugs to receive U.S. approval after 13 years but has disappointed investors with poor physician adoption and low sales- only 23.7 million for 2013. Vivus has at least seven patents in the United States on Qsymia, the earliest of which expires in June 2020. However, Actavis claims that the patents were either invalid, unenforceable, or would not be infringed by its generic drug.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins